EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 54 / No 4 (December 2022) J Extra Corpor Technol, 54 4 (2022) 318-323 References
Free Access
Issue
J Extra Corpor Technol
Volume 54, Number 4, December 2022
Page(s) 318 - 323
DOI https://doi.org/10.1051/ject/202254318
Published online 15 December 2022
  1. Raffini L. Anticoagulation with VADs and ECMO: Walking the tightrope. Hematology (Am Soc Hematol Educ Program). 2017;2017:674–80. [CrossRef] [PubMed] [Google Scholar]
  2. Paden ML, Conrad SA, Rycus PT, et al. Extracorporeal Life Support Organization Registry Report 2012. ASAIO J. 2013;59:202–10. [CrossRef] [PubMed] [Google Scholar]
  3. Arnold P, Jackson S, Wallis J, et al. Coagulation factor activity during neonatal extra-corporeal membrane oxygenation. Intensive Care Med. 2001;27:1395–400. [CrossRef] [PubMed] [Google Scholar]
  4. Bembea MM, Annich G, Rycus P, et al. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: An international survey. Pediatr Crit Care Med. 2013;14:e77–84. [Google Scholar]
  5. Extracorporeal Life Support Organization. ELSO Anticoagulation Guideline. Ann Arbor, MI: ELSO; 2014. Available at: https://www.elso.org/portals/0/files/elsoanticoagulationguideline8-2014-table-contents.pdf. Accessed September 15, 2021. [Google Scholar]
  6. Institute for Healthcare Improvement. How to Improve-Improvement Methods. Available at: http://www.ihi.org/IHI/Topics/Improvement/ImprovementMethods/HowToImprove/. Accessed September 16, 2021. [Google Scholar]
  7. Doran GT. There’s a S.M.A.R.T. way to write management’s goals and objectives. Manage Rev. 1981;70:35–6. (AMA FORUM). [Google Scholar]
  8. Berg M. Problems and promises of the protocol. Soc Sci Med. 1997;44:1081–8. [CrossRef] [Google Scholar]
  9. Hattersley PG, Hayse D. The effect of increased contact activation time on the activated partial thromboplastin time. Am J Clin Pathol. 1976;66:479–82. [CrossRef] [PubMed] [Google Scholar]
  10. Ranucci M, Cotza M, Isgrò G, et al. Surgical Clinical Outcome REsearch (SCORE) Group. Anti-factor Xa-based anticoagulation during extracorporeal membrane oxygenation: Potential problems and possible solutions. Semin Thromb Hemost. 2020;46:419–27. [CrossRef] [PubMed] [Google Scholar]
  11. Searles B, Nasrallah F, Darling E, et al. How does the age of a blood sample affect it’s activated clotting time? Comparison of eight different devices. J Extra Corpor Technol. 2002;34:175–7. [Google Scholar]
  12. Uden DL, Payne NR, Kriesmer P, et al. Procedural variables which affect activated clotting time test results during extracorporeal membrane oxygenation therapy. Crit Care Med. 1989;17:1048–51. [CrossRef] [PubMed] [Google Scholar]
  13. Nankervis CA, Preston TJ, Dysart KC, et al. Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation. ASAIO J. 2007;53:111–4. [CrossRef] [PubMed] [Google Scholar]
  14. Bembea MM, Schwartz JM, Shah N, et al. Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. ASAIO J. 2013;59:63–8. [CrossRef] [PubMed] [Google Scholar]
  15. Maul TM, Wolff EL, Kuch BA, et al. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2012;13:e363–71. [Google Scholar]
  16. Khaja WA, Bilen O, Lukner RB, et al. Evaluation of heparin assay for coagulation management in newborns undergoing ECMO. Am J Clin Pathol. 2010;134:950–4. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.